America February 5, 2026
Eikon’s Upsized $381M IPO Ignites Nasdaq Debut
Oncology-focused biopharmaceutical firm Eikon Therapeutics stepped onto the public stage Thursday, as Eikon’s Upsized $381M IPO powered its Nasdaq debut…
America February 5, 2026
Oncology-focused biopharmaceutical firm Eikon Therapeutics stepped onto the public stage Thursday, as Eikon’s Upsized $381M IPO powered its Nasdaq debut…
By Rachel Moore